Identification
- Brand Names
- Nauzene
- Generic Name
- Fructose
- DrugBank Accession Number
- DB04173
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
Structure for Fructose (DB04173)
- Weight
- Average: 180.1559
Monoisotopic: 180.063388116 - Chemical Formula
- C6H12O6
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Nausea ••• ••••• Symptomatic treatment of Upset stomach ••• ••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UMaltoporin Not Available Escherichia coli (strain K12) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Fructosteril (Fresenius) / Levugen (Baxter) / lnulon
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Anti Nausea Fructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL) Liquid Oral Rite Aid 1996-06-12 2017-11-04 US 
Anti Nausea Fructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL) Liquid Oral Meijer Distribution 1996-08-21 2017-11-01 US Anti Nausea Fructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL) Liquid Oral RUGBY LABORATORIES 2020-09-09 Not applicable US Anti Nausea Fructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL) Liquid Oral Kroger 2000-10-04 2017-11-01 US Anti Nausea Fructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL) Liquid Oral Cardinal Health 2020-07-27 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Anti Nausea Fructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL) Liquid Oral Safeway 2007-07-30 2018-05-15 US Anti Nausea Fructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL) Liquid Oral Kroger 2000-10-04 2017-11-01 US Anti Nausea Fructose (1.87 g/5mL) + D-glucose monohydrate (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL) Liquid Oral Medicine Shoppe International 2008-02-06 2013-06-09 US Anti Nausea Fructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL) Liquid Oral H.E.B. 1995-11-22 2017-09-08 US Anti Nausea Fructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL) Liquid Oral RUGBY LABORATORIES 2020-09-09 Not applicable US
Categories
- ATC Codes
- V06DC02 — Fructose
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as c-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a C-glycosidic bond.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- C-glycosyl compounds
- Alternative Parents
- Pentoses / Tetrahydrofurans / Secondary alcohols / Hemiacetals / Polyols / Oxacyclic compounds / Primary alcohols / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic heteromonocyclic compound / C-glycosyl compound / Hemiacetal / Hydrocarbon derivative / Monosaccharide / Organoheterocyclic compound / Oxacycle / Pentose monosaccharide / Polyol
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- L-fructofuranose (CHEBI:43703)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- WR469VI1J3
- CAS number
- Not Available
- InChI Key
- RFSUNEUAIZKAJO-AZGQCCRYSA-N
- InChI
- InChI=1S/C6H12O6/c7-1-3-4(9)5(10)6(11,2-8)12-3/h3-5,7-11H,1-2H2/t3-,4-,5+,6-/m0/s1
- IUPAC Name
- (2S,3R,4R,5S)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol
- SMILES
- OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O
References
- Synthesis Reference
Larry W. Peckous, "Integrated process for producing crystalline fructose and a high-fructose, liquid phase sweetener." U.S. Patent US5656094, issued 0000.
US5656094- General References
- Not Available
- External Links
- PDB Entries
- 1zx5 / 2cgj / 2cgl
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 3 Not Yet Recruiting Treatment Female Infertility 1 3 Recruiting Treatment Female Infertility 1 2 Terminated Supportive Care Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD 1 2 Terminated Treatment Melanoma 1 1 Completed Treatment Colorectal Cancer / Head And Neck Cancer / Metastatic Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Liquid Oral Solution Intravenous 5 % Solution Oral Powder Intravenous 50 mg/1ml Injection Intravenous 10 % Injection Intravenous 5 % Injection, solution Intravenous Injection, solution Parenteral Injection, solution Parenteral 30 % Injection, solution Parenteral 70 % Injection, solution Parenteral 10 % Injection, solution Parenteral 20 % Injection, solution Parenteral 33 % Injection, solution Parenteral 5 % Injection, solution Parenteral 50 % Solution Oral 750 mg/1 Syrup Oral Tablet, chewable Oral Tablet Oral Solution Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1110.0 mg/mL ALOGPS logP -2.4 ALOGPS logP -2.8 Chemaxon logS 0.79 ALOGPS pKa (Strongest Acidic) 10.28 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 110.38 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 36.36 m3·mol-1 Chemaxon Polarizability 16.3 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.6923 Blood Brain Barrier + 0.7551 Caco-2 permeable - 0.8511 P-glycoprotein substrate Non-substrate 0.6415 P-glycoprotein inhibitor I Non-inhibitor 0.9343 P-glycoprotein inhibitor II Non-inhibitor 0.9704 Renal organic cation transporter Non-inhibitor 0.8814 CYP450 2C9 substrate Non-substrate 0.8519 CYP450 2D6 substrate Non-substrate 0.8504 CYP450 3A4 substrate Non-substrate 0.6607 CYP450 1A2 substrate Non-inhibitor 0.9365 CYP450 2C9 inhibitor Non-inhibitor 0.9507 CYP450 2D6 inhibitor Non-inhibitor 0.9575 CYP450 2C19 inhibitor Non-inhibitor 0.9252 CYP450 3A4 inhibitor Non-inhibitor 0.9846 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9767 Ames test Non AMES toxic 0.9391 Carcinogenicity Non-carcinogens 0.9398 Biodegradation Ready biodegradable 0.6874 Rat acute toxicity 1.0362 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9772 hERG inhibition (predictor II) Non-inhibitor 0.9115
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0nvj-9800000000-a432e9a4475e87b9a71b Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-01pk-0900000000-df2086c5a56487e49897 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0l2r-8900000000-78d3f75e89cbe1755f56 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-01vw-9600000000-4da68ffd87d4c108781e Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-9800000000-e36486202cb9328cfca8 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-052p-9000000000-2c038da11011ebdbef71 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-054o-9000000000-dcf234c5d16e3d558b09 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 137.6725761 predictedDarkChem Lite v0.1.0 [M-H]- 134.42352 predictedDeepCCS 1.0 (2019) [M+H]+ 136.7635761 predictedDarkChem Lite v0.1.0 [M+H]+ 136.8191 predictedDeepCCS 1.0 (2019) [M+Na]+ 137.3195761 predictedDarkChem Lite v0.1.0 [M+Na]+ 143.09967 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Unknown
- General Function
- Virus receptor activity
- Specific Function
- Involved in the transport of maltose and maltodextrins, indispensable for translocation of dextrins containing more than three glucosyl moieties. A hydrophobic path ("greasy slide") of aromatic res...
- Gene Name
- lamB
- Uniprot ID
- P02943
- Uniprot Name
- Maltoporin
- Molecular Weight
- 49912.005 Da
Drug created at June 13, 2005 13:24 / Updated at September 28, 2021 21:54